The aim of this paper is to review the inhibitors of apoptosis proteins, a recently discovered group of caspase inhibitors. We will brie¯y review the relevance of apoptosis in prostate cancer and some of the control mechanisms, before describing the structure, function and regulation of these molecules. Lastly, we will consider the evidence for the role that IAPs may have in cancer and the implications for prostate cancer in particular. Prostate Cancer and Prostatic Diseases (2001) 4, 28±32.
Background
Early prostate cancer is eminently treatable but it is well recognised that no curative therapy is available once the cancer has spread beyond the prostate. 1 While prostate cancer initially responds well to androgen deprivation, this treatment results in the development of an androgenindependent phenotype that is resistant to programmed cell death (apoptosis); 2 and it is clear that a better understanding of this process could lead to the development of improved therapeutic strategies.
The apoptotic pathway
Apoptosis is the process by which cells die under normal conditions. This physiological process is genetically mediated 3 following a speci®c pathway that is activated in response to a death signal ( Figure 1 ). This process is distinct from necrosis and does not excite a signi®cant in¯ammatory response in the surrounding tissue. For review see Watson and Fitzpatrick. 4 The caspases This group of cytosolic, cysteine proteases plays a fundamental role in health and disease. Some have roles in in¯ammation, while others are involved in apoptosis, 5 both as activators of downstream caspases as well as actual effectors of cellular proteolysis, ie caspases 3 and 7. 6 In response to a cell death signal, a sequence of events is initiated which usually involves the release of cytochrome c from the mitochondria which is an irreversible step (see Figure 1 ), 7 and which cumulates in the formation of active caspases from inactive proforms, bringing about substrate cleavage and cell death.
In preliminary experiments we have demonstrated that there is an alteration in pro-caspase-3 expression and location in prostate cancer paraf®n embedded sections. 8 (For review see Coffey et al. 9 ). Thiol depletion has been shown in vitro to effectively activate caspase 3 and this may in the future possibly provide a therapeutic strategy. 10 
Inhibitors of the apoptotic pathway
Two classes of cellular proteins are known to inhibit caspase activity. The anti-apoptotic members of the Bcl-2 family; and the inhibitors of apoptosis proteins (IAPs) family of proteins.
Bcl-2
These proteins are well established as important regulators of apoptosis. 11 Anti-apoptotic members such as Bcl-2 and Bcl-x can form homodimers or heterodimers with pro-apoptotic members of the Bcl-2 family, such as Bad or Bax. 12 The ratio of pro to anti apoptotic heterodimers determines by interaction with the mitochondrial membrane, whether or not an ef¯ux of cytochrome c will occur, upon which the lower end of the caspase cascade is dependent for activation in most cases 13 (see Figure 1) .
The expression of these molecules in prostate cancer has been investigated using immunohistochemistry, and the expression of Bcl-2, 17 Bcl-x L and Mcl-1 increases during the progression of prostate cancer. 14 Furthermore, on the withdrawal of trophic factors, prostate carcinoma cells up-regulate Bcl-2 expression in contrast to benign prostatic hyperplasia (BPH) cells which up-regulate p53 expression. 15 The inhibitor of apoptosis proteins
The IAPs are a recently identi®ed group of anti-apoptotic proteins and were originally described in Baculovirus, 16 a virus that infects insect cell cultures. Subsequent work identi®ed homologous genes in insect 17 and mammalian cells. So far ®ve members have been identi®ed in human cells: NAIP, cIAP-1, cIAP-2, XIAP and survivin.
NAIP was the ®rst human IAP to be discovered, 18 due to its absence in most cases of severe spinal muscle atrophy; a rare autosomal recessive disorder of infancy, characterised by progressive apoptosis of spinal muscle motor neurones. 19, 20 Subsequent work con®rmed that NAIP was cytoprotective 21 and homologous sequence tagging led to the discovery of X-linked IAP (XIAP/hILP). 22 Human IAP-1 (hIAP-1/ cIAP-2) and human IAP-2 (hIAP-2/cIAP-1) were identi®ed during biochemical puri®cation of the TNF receptor. 23 
IAP structure
Although they are varied in size IAPs have a number of important similarities. At their N-terminus they possess a virtually unique motif, the Baculovirus inhibitory repeat (BIR, see Figure 2 ). This consists of between one and three imperfect amino acid repeats, 24 each 60 ± 80aa in length, which fold into a hydrophobic core with hydrophilic surface residues. 25 The core contains a zinc-binding site that is capable of supporting protein ± protein interactions; as well as possible sites of phosphorylation. It is unclear why there is variation in the number of BIR domains in IAPs (see Table  1 ) and at least in some, only one of the BIRs is required for anti-caspase activity. 26 XIAP, cIAP-1 and cIAP-2 (see Table 1 ) contain zinc RING (really interesting new gene) ®nger at the c-terminus (see Figure 2 ). This motif is not unique and is present in many proteins where it is required for interactions with other proteins. 25 Survivin lacks the zinc RING ®nger but instead possesses a particular three dimensional`coiled coil' protein arrangement. Removal of this blocks the antiapoptotic effect by dissociating survivin from the mitotic spindle where it is required at the G2/M phase of the cell cycle. 27 This observation supports the theory that the original function of IAPs may have been to act as facilitators in cytokinesis, as yeasts contain IAPs, but no caspases or apoptotic programme and IAP mutations cause abnormalities of cell division. 28 Despite this, structural homology between different organisms allows insect and viral IAPs to inhibit mammalian caspases. 29 cIAP-1 and cIAP-2 also possess a caspase recruitment domain (CARD). 30 This motif, often found in apoptotic signaling proteins, is thought to have a role in substrate recognition. While all the IAPs except NAIP have been shown to inhibit caspases, 18 XIAP has the strongest binding af®nity for the caspases and may well be the physiological inhibitor. 24 
Mechanism of action
IAPs have been shown to protect cells from a wide range of apoptotic triggers including Fas ligation, Bax, activated caspases, cytochrome c, TNFa, some chemotherapeutic agents, viral infection and radiation. 31 ± 36 All IAPs (except NAIP whose anti-apoptotic mechanism remains unclear), have been shown to be able to bind to and inhibit activated caspases 3 and 7, 37 furthermore cIAP-1, cIAP-2 and XIAP have also been shown to inhibit the activation of caspase 9, 38 which activates caspases 3 and 7 (see Figure 1) .
Other anti-apoptotic mechanisms have also been described. In response to TNFa, NF-kB is activated, and this leads to increased levels of cIAP-1 and 2, and also TRAF1 and TRAF2 39 (TNF receptor associated factor). cIAP-1 and 2 can bind TRAF 1 and 2, 23 and these molecules can associate at the cytosolic death domain, and thereby prevent caspase 8 activation in response to the death signal. 39 Other interactions reported include cIAP-2 with RIP kinase 40 and XIAP with the BMP receptor. 41 (The latter interaction is mediated via the RING ®nger.)
Regulation
Expression of some IAPs is known to be regulated by NF-kB. 35, 42, 43 This transcription factor that is key to so many cellular processes is believed to have an important role in in¯ammatory and neoplastic diseases. 44 Inhibitors of NF-kB activation such as pyrrolidine dithiocarbamate (PDTC) and genestein, have been shown to cause an increase in prostate cell apoptosis in response to agents such as tumour necrosis factor a and DNA-damaging agents 45, 46 (but not radiation 47 ). It is tempting to think that this could in part be due to the blockade of IAP activation. However, NF-kB exerts its anti-apoptotic effects via a number of different molecules including the Bcl-2 homologues A1/B¯-1 48 and Bcl-X L . 49 NF-kB can also induce survival factors such as IL-6 and IL-2 receptor. 50 It will be interesting to see if NF-kB is able to express these anti-apoptotic proteins in prostate cancer cells. The other signi®cant point to make with regard to NF-kB is that cIAP-1 and cIAP-2 have been shown to actually activate NF-kB, 51 (and see review 50 ), suggesting that cell survival involving the IAPs and NF-kB may take the form of a positive feedback loop.
With regards to what actually inactivates IAPs, the evidence is limited, however it has been shown that in response to an apoptotic trigger, cIAP-1 and XIAP can The role of apoptosis proteins KR McEleny et al undergo ubiquitination and degradation in a process requiring an intact RING domain. 52 Also there is some published evidence, at least with regard to XIAP, that the IAPs may themselves be targets for activated caspases. 53 
IAPs and cancer
Survivin was originally identi®ed using hybridization screening of a human genomic library with cDNA for the clotting factor Xa receptor, effector cell protease receptor-1 54 (EPR-1). This membrane receptor which is found in leukocytes, endothelial cells and smooth muscle cells has been shown to have roles in both in¯ammation (including angiogenesis) and mitogenic signaling. 55 Survivin is expressed only in foetal tissue under normal conditions, 56 although mRNA can also be detected in adult thymus and to a lesser degree, in placenta. 54 Survivin has also been shown to be strongly expressed in endothelial cells in granulation tissue. 57 This suggests that survivin may also have an important role in angiogenesis, another key event in carcinogenesis.
Survivin expression has been demonstrated using immunohistochemistry to be present in the majority of carcinomas tested including lung, pancreas and colon. 54 It has also been found in high grade, (but not low grade) lymphomas. Interestingly, transfection of HeLa cells with both survivin and EPR-1 abrogates the anti-apoptotic effect of survivin transfection alone. 58 A number of studies have looked at survivin expression using immunohistochemistry. In neuroblastoma expression has been shown to correlate with a more aggressive grade and unfavourable histology. 59 In breast cancer survivin expression was strongly associated with Bcl-2 expression and a reduced apoptotic index, 60 (patients with a reduced apoptotic index had a worse survival rate than those with a high apoptotic index). In gastric cancer survivin expression was also associated with Bcl-2 expression and a reduced apoptotic index, as well as expression of mutated p53. 61 Survivin expression in colorectal cancer has also been investigated. One study found it to be associated with Bcl-2 expression and a reduced apoptotic index, (but not with mutant p53 expression) and contributed to a worse ®ve-year survival. 62 A separate preliminary study in recurrent stage II colorectal cancer showed that although survivin expression was independent of both Bcl-2 and p53 expression, it was associated with an increased risk of death. 63 In skin cancers survivin expression has been identi®ed in 81% of basal cell carcinomas, 92% of squamous cell carcinomas 64 and 93% of malignant melanomas. 65 Other IAPs have also been investigated. cIAP-1, cIAP-2 and XIAP have been identi®ed in 12 different malignant glioma cell lines. 66 With regards to prostate cancer, survivin expression has been demonstrated in the PC3 and DU145 cell lines. 31 Expression of survivin protein and mRNA has also been discussed in ®ve formalin-®xed, paraf®n-embedded sections using immunohistochemistry and in situ hybridisation, 54 but no published data is available. In addition, immunohistochemistry has also been used to demonstrate the presence of cIAP-1 and cIAP-2 in prostate cancer. 67 Data has been presented on a group of 23 patients who had undergone neoadjuvant androgen ablation therapy prior to radical prostatectomy. The percentage of cells demonstrating positive expression of cIAP-1, increased from 4.2% prior to androgen ablation, to 65.2% after androgen ablation. Also the expression of cIAP-2 increased from 4.2% to 73.9% after treatment.
The observation that IAP expression actually increases with androgen blockade, implies a potentially important role for IAPs in the development of apoptotic resistance in androgen independent prostate cancer.
Conclusions
Although the mechanism is only partially understood, research has so far revealed that the regulation of apoptosis in cells is subtle and complex. This is to be expected of a system that is of such crucial importance. In prostate cancer, dysfunctional apoptotic machinery has profound implications. Expression of IAPs may well contribute to the development of prostate cancer, but further research is required. Inevitably this will provide the clinician with new therapeutic strategies in the treatment of cancer.
